David T. Curiel
David Terry Curiel (born 1956) is an American cancer biologist. He is a professor of Radiation Oncology at Washington University School of Medicine and Director of the Biologic Therapeutics Center. In 1995, Curiel led a research team who were the first to develop a vaccine based on messenger RNA. Although they published proof of concept, he could not continue testing due to a lack of funding. In 2021, Curiel developed a vaccine that targets the SARS-CoV-2 virus through the nose.
David T. Curiel | |
|---|---|
| Born | 1956 (age 67–68) |
| Academic background | |
| Education | BSc, Chemistry, 1978, West Georgia College MD, 1982, Emory University School of Medicine PhD, Virology, 2002, University of Groningen |
| Thesis | Genetic capsid modification for adenovirus retargeting (2002) |
| Academic work | |
| Institutions | Washington University in St. Louis University of Alabama at Birmingham University of North Carolina at Chapel Hill |
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.